| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.01 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.08 | 0.01 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.085 | 0.01 |